TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The U.S. Department of Justice said Michigan physician Jonathan Decker was convicted in a case involving more than 2 million stimulant pills distributed through the Done ADHD telehealth platform. Separately, Click Therapeutics said the FDA cleared Motivista as an adjunctive digital treatment for negative symptoms of schizophrenia in outpatient care. The source report also noted growing discussion of AI-related anxiety in therapy, but offered no further detail on its prevalence or clinical effects.
Michigan physician Jonathan Decker, MD, was convicted in a case involving the distribution of more than 2 million stimulant pills, including Adderall, through the Done ADHD telehealth platform, according to the U.S. Department of Justice. In separate psychiatry news, the FDA cleared Motivista as an adjunctive digital therapeutic for negative symptoms of schizophrenia in outpatient care, Click Therapeutics said.
The Justice Department said Decker was convicted of peddling more than 2 million stimulant pills, including amphetamine-dextroamphetamine salts, the medication commonly known by the brand name Adderall. The report identifies Done ADHD as the telehealth platform involved. It does not provide the trial date, the specific counts of conviction, details of the evidence, or any sentence.
Click Therapeutics said the FDA cleared Motivista for use as an adjunct to care for negative symptoms of schizophrenia among outpatients. The source describes this as an FDA clearance, not as a replacement for other treatment. It does not state the product’s precise intended-use instructions, availability, or the evidence and conditions tied to the agency’s decision.
The same October 7 psychiatry roundup highlighted anxiety about artificial intelligence as an increasingly prominent subject in therapy sessions, citing The New York Times. That item contains no survey results or clinical data establishing how common the concern is. The roundup also reported that the FDA was seeking public feedback on ibogaine drug development to inform the design of future early-stage clinical trials.
Oversight and New Digital Care
The conviction puts a high-volume stimulant prescribing case involving a telehealth ADHD platform in the public record. Stimulants such as Adderall are prescription medicines, and the reported quantity makes the case relevant to scrutiny of prescribing practices and oversight in remote care. The source, however, does not establish that the case represents all telehealth prescribing or describe any broader regulatory findings.
Motivista’s clearance marks a separate development in digital mental health care: a software-based therapeutic is authorized for use alongside outpatient care for a defined set of schizophrenia symptoms. That could add a digital option for clinicians and patients, but clearance alone does not establish how widely it will be used or what outcomes patients will experience in routine care.
AI anxiety’s appearance in therapy coverage points to a concern clinicians may encounter as AI tools become part of everyday life. The source provides no basis to estimate its frequency, diagnose it as a distinct condition, or say that AI use causes a mental health disorder. These items matter in different ways: one concerns alleged medication distribution and criminal accountability, another a regulatory decision, and the third a reported topic of conversation.
digital therapeutic for schizophrenia
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Three Separate Psychiatry Developments
The source is a psychiatry news roundup published by MedPage Today on October 7, 2026, rather than a single detailed account of all three developments. Its short summaries cite the Justice Department for the conviction, Click Therapeutics for the Motivista clearance, and The New York Times for the observation about AI anxiety in therapy.
The roundup places the items alongside other developments, including FDA efforts to gather feedback on ibogaine trial development, research on unmet treatment needs, and a study of Medicaid-enrolled young people with opioid use disorder. Those reports are not evidence about Decker’s case or Motivista, and the source does not link the separate findings. The central developments should therefore be understood on their own terms, with each claim tied to its cited source.
“The FDA cleared the prescription digital therapeutic Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care.”
— Click Therapeutics, as summarized by MedPage Today
smart pill organizer with medication reminders
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Case Details and Evidence Still Missing
The available summary does not identify the charges, verdict date, trial evidence, or sentence in Decker’s case. It also does not explain which conduct the conviction covered beyond the stated pill distribution or provide a response from Decker or Done ADHD. Those details cannot be inferred from the reported quantity alone.
For Motivista, the summary does not give the FDA’s decision documents, the supporting trial results, practical access information, or the product’s specific conditions of use. The claim about AI anxiety likewise has no accompanying estimate, study design, or account of how therapists are responding. These limits leave the scale and practical consequences of the latter two developments unclear from this report.
home blood pressure monitor digital
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Court and Product Details to Follow
Further information about Decker’s case would be needed to establish the precise offenses, any post-trial proceedings, and the sentence, if one has been issued. The source does not say when a sentencing hearing is scheduled or whether an appeal is planned. Readers should distinguish those unresolved legal details from the reported fact of the conviction.
For Motivista, the next useful details would include the FDA’s full clearance information, the clinical evidence and intended-use guidance, and when the product will be available to outpatient providers. The roundup says the FDA is soliciting feedback on ibogaine development to help shape future early-phase trial design, but gives no deadline or planned trial milestones. It provides no specific next event or timetable for research into AI-related anxiety.
ADHD telehealth medication management
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who was convicted in the stimulant-pill case?
Jonathan Decker, MD, of Michigan, was reported convicted, according to the U.S. Department of Justice as summarized by MedPage Today.
How many pills were involved?
The source says the case involved more than 2 million stimulant pills, including amphetamine-dextroamphetamine salts, commonly known as Adderall. It does not provide a more detailed accounting.
What is Motivista cleared to do?
Click Therapeutics said the FDA cleared Motivista as an adjunctive digital therapeutic for negative symptoms of schizophrenia in outpatient care. The source does not provide full instructions or evidence details.
Does the report show that AI anxiety is widespread?
No. It says anxiety about AI is becoming a prominent therapy topic, citing The New York Times, but gives no prevalence figures or survey data.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
